Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics’ earnings trailed consensus as EPS of -$1.05 came in below the -$1.03 estimate (difference -$0.02) for the second fiscal quarter of 2026, reported August 6, 2026. Revenue rose 278.7% to roughly $0.3 million, up from $75,000.00 a year ago, reflecting the company’s clinical-stage profile with work centered on pipeline programs such as VRDN-001, VRDN-002, and VRDN-003. With gross profit matching revenue at roughly $0.3 million, the quarter’s results were dominated by operating expense, as operating income was a loss of about $126.3 million. Net income was a loss of roughly $127.1 million, down 26.2% from a net loss of -$100.7 million a year ago, while EPS of -$1.05 was down 5.0% from -$1.00 in the prior-year period. For the next period, consensus calls for EPS of -$0.99 on revenue of $4.0 million.